Neurology

Clevenger, a professor of nursing at Emory University, shares practical strategies to manage agitation in Alzheimer disease, emphasizing that this symptom is treatable.

Semaglutide did not slow AD progression in phase 3 evoke trials. UK and US experts express disappointment but laud value of outcomes to continuing research.

New data reveals lecanemab's significant impact on amyloid-beta protofibrils in Alzheimer disease, showcasing its potential to slow disease progression.

Two-year structured lifestyle "recipe" slowed cognitive aging and enhanced both cardiovascular and sleep health in older adults at risk for cognitive decline.

Your daily dose of the clinical news you may have missed.

Nearly one-third of caregivers hesitate to discuss agitation in a patient with AD. Emory's Clevenger, shares why and how clinicians can proactively address this barrier.

Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.

Emory's Clevenger discusses the neurotransmitter dysregulation behind agitation in AD and why memory-focused care doesn't address behavioral symptoms.

New safety and biomarker results from MK-2214 and MK-1167 advance Merck’s dual approach to Alzheimer therapy.

Two-thirds of participants experienced clinically meaningful response within 3 months; effects sustained through 12 months with mild adverse event profile.

Clevenger reviews survey findings behind the recent report "The Agitation Blindspot in Alzheimer’s Care."

Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.

J&J halts phase 2b AuTonomy trial after anti-tau antibody posdinemab fails to slow clinical decline, marking another setback for tau-targeting therapeutics.

Evoke trials testing semaglutide for Alzheimer disease missed primary endpoint, failing to demonstrate benefit on cognition despite positive effects on disease markers.

Topline data show the factor XIa inhibitor cut ischemic stroke risk without increasing ISTH major bleeding, pointing to a possible new option for secondary prevention.

Life-course analysis sheds light on how movement patterns influence brain resilience, giving clinicians new context for counseling about dementia prevention.

Eisai and Acumen Therapeutics will present new data in areas including long-term outcomes, brain delivery strategies, and early-stage Alzheimer disease.

UK neurodivergent adults report strong views on neurodiversity terminology, emphasizing correct usage and its role in stigma, identity, and communication.

Individuals who have chronic widespread pain showed a 75% increased risk of developing hypertension compared to fellow UK Biobank participants who were pain-free.

Your daily dose of the clinical news you may have missed.

Higher surprisal scores, measuring how atypical a daily experience is, increased migraine odds by 86% at 12 hours and 115% at 24 hours in new cohort study.

A geriatric psychiatrist's clinical pearls on agitation in AD, incluiding behavioral cues, triggers, and evidence-based treatment strategies for primary care.

Many caregivers, both paid and unpaid, miss or misinterpret agitation symptoms in Alzheimer disease, fueling stress, stigma, and delayed medical support.

Indiana University study found that integrating patient-reported outcome questionnaires with machine learning boosts dementia diagnoses by 31% in primary care settings.

TMS 2025: Katrina Wugalter, MA, discusses research showing that age—not menopause stage—drives brain volume decline, and how lifestyle factors can help preserve brain health in midlife women.